Quick-releasing talbet in vagina and its preparing method

An immediate-release tablet and vaginal technology, which is applied in the direction of pharmaceutical formula, medical preparations containing active ingredients, pill delivery, etc., to achieve the effect of good patient compliance, simple and practical preparation method, and less discomfort

Inactive Publication Date: 2004-02-11
NINGBO LIWAH PHARM CO LTD
View PDF6 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The technical problem to be solved by the present invention is to overcome the shortcomings of the vaginal drug dosage forms disclosed in the above-mentioned patent docu...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach 1

[0036] Misoprostol vaginal immediate release tablet, its formula is (1000):

[0037] Misoprostol dispersion 2.5g (converted to pure misoprostol 25mg)

[0038] Mannitol 94g

[0039] Microcrystalline Cellulose 40g

[0040] Croscarmellose Sodium 6g

[0041] pvp K30 4g

[0042] Magnesium Stearate 4g

[0043] The preparation method of misoprostol vaginal immediate release tablet is:

[0044] Step 1. Grinding and sieving: Grinding and sieving the above-mentioned drugs and auxiliary materials respectively, and the particle size of the fine powder is about 50 μm.

[0045] Step 2. mixing: take misoprostol dispersion and pharmaceutical adjuvant fine powder by prescription quantity, 2 / 3 disintegrant wherein and whole lubricant fine powder are reserved for subsequent use, then principal agent fine powder and the rest The fine powder of auxiliary materials is mixed evenly.

[0046] Step 3. Granulation: with 7.5% PVP K30 Appropriate amount of aqueous solution or 70% ...

Embodiment approach 2

[0052] Levofloxacin vaginal immediate release tablet, its formula is (1000):

[0053] Levofloxacin 100g

[0054] Mannitol 39g

[0055] Gelatin 10g

[0056] PEG6000 6g

[0057] The preparation method of levofloxacin vaginal immediate release tablet comprises:

[0058] Step 1. Dosing: crush and sieve levofloxacin to obtain a fine powder with a particle size of 50 μm. Take 700ml of pure water, add the prescribed amount of gelatin, heat to 60°C and stir to dissolve, add mannitol and PEG6000 to dissolve, and cool to room temperature. Then add levofloxacin fine powder, stir to form a suspension, add pure water to 750ml. If necessary, a suitable pharmaceutically acceptable surfactant is added to make a stable suspension.

[0059] Step 2. Dispensing of the medicinal solution: Quantitatively dispense the above medicinal solution into the PVC multiple depression models, 0.75ml for each depression model.

[0060] Step 3. Freeze-drying: put the PVC model wrench containing the medic...

Embodiment approach 3

[0066] Azithromycin vaginal immediate release tablet, its formula is (1000 tablets):

[0067] Azithromycin 25g

[0068] Lactose 30g

[0069] Microcrystalline Cellulose 15g

[0070] Crospovidone 4.5g

[0071] pvp K30 3g

[0072] Magnesium Stearate 3g

[0073] The preparation method of the azithromycin vaginal immediate release tablet is the same as that of embodiment 1.

[0074] Tablet weight 800mg hardness 2.0kg / cm 2

[0075] Determination of disintegration time limit: according to Chinese Pharmacopoeia 2000 edition, Chlorophytum improved method, measured disintegration time limit, disintegrated within 45 seconds; animal experiment: disintegrated within 60 seconds.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Sheet weightaaaaaaaaaa
Sheet weightaaaaaaaaaa
Login to view more

Abstract

The quick releasing vagina tablet includes various active medicinal components, such as antibiotic, antifungal, antiviral, hormone, prostanoid, etc.; and medicinal supplementary material stuffing, adhesive and disintegrating agent. The stuffing includes water soluble stuffing and water insoluble stuffing. The quick releasing vagina tablet, after contacting with vagina secretion, can disintegrate to disperse or dissolve so that it is absorbed via vagina mucous membrane to produce local treatment effect and made to enter body circulation to produce bodily treatment effect. It is convenient and accommodative.

Description

technical field [0001] The invention relates to a vaginal quick-release drug dosage form, in particular to a vaginal quick-release tablet and a preparation method thereof. Background technique [0002] In order to prevent and treat diseases, in addition to the commonly used gastrointestinal administration, there are many other routes and methods of administration, such as mucosal administration, that is, administration through the oral cavity, nasal cavity, eyes, rectum, skin, and vaginal mucosa. There are abundant capillaries under the mucous membranes of these parts. Drugs applied to the mucous membranes can directly enter the systemic circulation after absorption without passing through the physiological environment of the digestive tract, which can avoid the first-pass effect of the liver, and is very suitable for stimulating the gastrointestinal tract. Drugs that are highly toxic, easily destroyed by gastric acid and digestive enzymes, and easily metabolized by the live...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/20A61K31/5383A61K31/5575A61K31/7048A61P15/02
Inventor 刘辉
Owner NINGBO LIWAH PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap